arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Hemab Therapeutics Holdings, Inc.

COAG

$45.54 ▲ +0.44 (+0.96%) at close

5 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

insights

Verdict pending

Sync financial data to generate a health grade for this company.

auto_awesome

Analytical Summary

Review the statement evidence below to form a view on COAG.

Market Cap $1.4B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -5.8% ↘

FCF / Share $-0.75 ↗

Trailing P/E —

Price / Book 3.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-22.69M

↓ -48.2% —

FCF / Share Free cash flow per share

$-0.75

↑ +95.4% —

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
EPS Growth YoY (%)	93.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-48.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-48.2% Weak Weak Year-over-year change in net income	-48.2% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	95.4% Excellent Excellent Year-over-year change in free cash flow	-66.3% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Effective Tax Rate (%) (%)	-0.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
FCF / Net Income (x)	1.00x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	—	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Return on Invested Capital (%)	-5.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	11.9% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-5.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-13.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-5.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	11.4% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-24%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Interest Coverage (x)	—	—	—	-4014.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	-5520.00x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-237.37M	$-49.86M	$-87.97M	—	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Basic EPS, GAAP (USD)	$-0.80	$-23.98	—	$-12.91	$-16.18
Free Cash Flow per Share (USD)	$-0.75	$-22.93	—	$-16.21	$-13.79
Book Value per Share (USD)	$15.09	$-209.96	—	—	—
Tangible Book Value per Share (USD)	$15.09	$-209.96	—	—	—
Basic Weighted Avg Shares (shares)	30.11M	946,000	—	946,000	946,000

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Working Capital (USD)	$451.05M	$156.24M	$181.87M	—	—
Total Equity (USD)	$454.27M	$-198.62M	$-176.63M	—	—

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗
Depreciation Expense (USD)	$75.00K	$73.00K	—	$77.00K	$75.00K
Net Income, GAAP (USD)	$-22.69M	$-22.69M	—	$-15.31M	$-15.31M
Operating Cash Flow (USD)	$-22.64M	$-21.58M	—	$-15.33M	$-13.03M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago

Hemab Therapeutics Holdings, Inc.

Analytical Summary

5-Year Financial Trajectory

Statement lens

Benchmark Lens

Compare COAG with peers